Ascendis Pharma A/S (ASND) Implied Volatility Current

Tracking ASND implied volatility helps you identify when options premiums on Ascendis Pharma A/S are historically cheap or expensive, and where the best trades are hiding. Ascendis Pharma A/S implied volatility reflects the market's expectation of future price movement: when ASND IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Ascendis Pharma A/S's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For ASND, tracking metrics like ASND IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on ASND signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where ASND implied volatility sits today versus where it has been. Our scanner ranks Ascendis Pharma A/S implied volatility against its historical range, surfaces extremes in ASND IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Ascendis Pharma A/S IV is rich or cheap — measure it, then act on it.